Active — Not RecruitingNot Applicable

PET-CT Predicting Lymph Nodes Metastasis

China280 participantsStarted 2023-11-01

Plain-language summary

This study is a single-center prospective clinical study that aims to evaluate the predictive value of preoperative 18F-FDG-PET-CT and 18F-FAPI-PET/CT for lymph node metastasis in patients with non-small cell lung cancer. The final pathological results were used to assess the predictive value of PET-CT for lymph node metastasis.

Who can participate

Age range20 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Solitary tumor, or multiple tumors with only ground-glass nodules (GGNs) apart from the primary lesion. * Diameter of the primary lesion ≤5cm, with a CTR between 0.5 and 1. * Pathological confirmation of non-small cell lung cancer (NSCLC) either before or during surgery. * No prior radiotherapy or chemotherapy for initial treatment. * No history of malignant tumors. Exclusion Criteria: * Locally advanced or distant metastasis. * Pleural dissemination observed during surgery. * History of malignant tumors. * Received neoadjuvant therapy. * Histopathological examination reveals lung malignancies other than non-small cell lung cancer (NSCLC).

What they're measuring

Predictive value of 18F-FDG-PET/CT and 18F-FAPI-PET/CT for lymph node metastasis

Timeframe: from enrollment to 1 month after surgery

Trial details

NCT IDNCT05970913

SponsorFudan University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-03-28

View on ClinicalTrials.gov More Non Small Cell Lung Cancer trials